FEDO

FEDO
FEDO
Print

Indigenous probiotic Lactobacillus strain LBS2

Background:
The probiotic strain LbS2, an indigenous isolate of healthy Indian gut, identified genotypically by 16S rRNA sequencing, characterized following the ICMR-OBT guidelines and investigated for its anti-inflammatory functions and cure for inflammatory bowel disease in a mouse model. The strain possesses probiotic attributes, such as acid and bile tolerance, hydrophobicity, auto- and coaggregation properties, and antimicrobial activity against Entero-aggregative E, coli (EAEC), and has been deposited at Microbial Type Culture Collection and Gene Bank (MTCC), Chandigarh under Budapest treaty with MTCC No. 5953. The draft genome sequence of LbS2 has been submitted to the NCBI gene bank under the accession number JPKN00000000. LbS2 treatment suppressed the levels of IL-12, TNF-alpha and IL-17A while inducing IL-10 and TGF- beta levels in the colonic tissues. Moreover, LbS2 increased the number of FoxP3+ Treg cells in the mesenteric lymph nodes and treatment with LbS2 or adoptive transfer of the Treg cells ameliorated colitis with improvement of macroscopic and histopathological features of colitis. The above effects were observed with both live and heat-killed LbS2 and mediated by Toll-like receptor 2 (TLR2) activation on the dendritic cells. A separate study showed that LbS2 significantly decreased cecal colonization of enteroaggregative E. coli, a frequent cause of persistent diarrhea in malnourished children, in a malnourished mouse model of infection in addition to restoration of the intestinal permeability barrier. Besides, live cells of LbS2 were found to increase the expression of proglucagon gene in enteroendocrine NC1H716 cells as well as secretion of GLP-1, whereas heat killed cells of LbS2 were found to induce GLP-1 secretion. In addition, the LbS2 was found to utilize FOS and inulin as efficiently as glucose
Technology Details:
The probiotic strain LbS2, an indigenous isolate of healthy Indian gut, identified genotypically by 16S rRNA sequencing, characterized following the ICMR guidelines and investigated for its anti-inflammatory functions and cure for inflammatory bowel disease in a mouse model